Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qiming Liao

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|June 28, 2005
Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patientsMartin Markowitz, Christina Hill-Zabala, Joseph Lang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 13, 2006
Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or StavudineJohn A Bartlett, Judy Johnson, Gisela Herrera, et al.
Forestry Research|November 28, 2025
Optimizing forest structure for sustainability: a review of structure-based management effects on stand qualityQiming Liao, Quan Qiu, Jie Gao, et al.
Optics Express|December 19, 2025
In vacuum metasurface for optical microtrap arrayDonghao Li, Qiming Liao, Beining Xu, et al.
Pharmacotherapy|March 26, 2004
Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virusPeter J Ruane, Gary J Richmond, Edwin DeJesus, et al.
AIDS (London, England)|August 2, 2008
First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North AmericaBenjamin Young, Kathleen Squires, Parul Patel, et al.
BMC Infectious Diseases|June 11, 2003
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patientsJeffrey P Nadler, Joseph C Gathe, Richard B Pollard, et al.
BMC Infectious Diseases|April 12, 2005
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimensSusan Swindells, Calvin J Cohen, Daniel S Berger, et al.
AIDS Research and Therapy|April 1, 2008
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERTKimberly Y Smith, Winkler G Weinberg, Edwin DeJesus, et al.
The Journal of Infectious Diseases|November 4, 2005
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjectsJoel E Gallant, Allan E Rodriguez, Winkler G Weinberg, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Journal of Acquired Immune Deficiency Syndromes (1999)|June 28, 2005
Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patientsMartin Markowitz, Christina Hill-Zabala, Joseph Lang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 13, 2006
Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or StavudineJohn A Bartlett, Judy Johnson, Gisela Herrera, et al.
Forestry Research|November 28, 2025
Optimizing forest structure for sustainability: a review of structure-based management effects on stand qualityQiming Liao, Quan Qiu, Jie Gao, et al.
Optics Express|December 19, 2025
In vacuum metasurface for optical microtrap arrayDonghao Li, Qiming Liao, Beining Xu, et al.
Pharmacotherapy|March 26, 2004
Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virusPeter J Ruane, Gary J Richmond, Edwin DeJesus, et al.
AIDS (London, England)|August 2, 2008
First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North AmericaBenjamin Young, Kathleen Squires, Parul Patel, et al.
BMC Infectious Diseases|June 11, 2003
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patientsJeffrey P Nadler, Joseph C Gathe, Richard B Pollard, et al.
BMC Infectious Diseases|April 12, 2005
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimensSusan Swindells, Calvin J Cohen, Daniel S Berger, et al.
AIDS Research and Therapy|April 1, 2008
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERTKimberly Y Smith, Winkler G Weinberg, Edwin DeJesus, et al.
The Journal of Infectious Diseases|November 4, 2005
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjectsJoel E Gallant, Allan E Rodriguez, Winkler G Weinberg, et al.
Pageof 3